The FDA is reassessing the approval of immune checkpoint inhibitors for treating advanced HER2-negative gastric adenocarcinoma, questioning their broad application regardless of patients’ PD-L1 expression levels.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
